IGMS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 112760 min ago

@ $15.41

Išleistas: 14 vas. 2024 @ 20:56

Grąža: -38.81%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: -4.82 %

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases...

Stats
Šios dienos apimtis	189 460
Vidutinė apimtis	294 208
Rinkos kapitalizacija	555.88M
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $-0.840 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.00
ATR14	$0.0260 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-14	Harler Mary Beth	Sell	0	Common Stock
2024-04-14	Harler Mary Beth	Sell	200 000	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	75 000	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	52 500	Stock Option (right to buy)
2024-04-14	Harler Mary Beth	Sell	92 500	Stock Option (right to buy)

INSIDER POWER
56.94
Last 99 transactions
Buy: 2 356 293 \| Sell: 614 616

Tūris Koreliacija

Ilgas: 0.08 (neutral)

Trumpas: 0.68 (moderate)

Signal:(70.97) Neutral

IGM Biosciences Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
LWAC	0.811

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

IGM Biosciences Inc Koreliacija - Valiuta/Žaliavos

-0.51
( weak negative )

-0.61
( weak negative )

-0.09
( neutral )

-0.39
( neutral )

0.53
( weak )

0.60
( weak )

IGM Biosciences Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$2.13M
Bruto pelnas:	$-6.15M (-288.59 %)
EPS:	$-4.71

FY	2023
Pajamos:	$2.13M
Bruto pelnas:	$-6.15M (-288.59 %)
EPS:	$-4.71

FY	2022
Pajamos:	$1.07M
Bruto pelnas:	$-9.53M (-891.77 %)
EPS:	$-5.16

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-5.37

Financial Reports:

No articles found.

IGM Biosciences Inc

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.